Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Rani Therapeutics Holdings ( (RANI) ) is now available.
Rani Therapeutics Holdings has entered into a loan agreement, which is expected to impact its financial operations. The agreement may influence the company’s market positioning and stakeholder interests.
The most recent analyst rating on (RANI) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.
Spark’s Take on RANI Stock
According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.
Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.
To see Spark’s full report on RANI stock, click here.
More about Rani Therapeutics Holdings
Average Trading Volume: 607,599
Technical Sentiment Signal: Sell
Current Market Cap: $33.84M
For an in-depth examination of RANI stock, go to TipRanks’ Overview page.